Article
ASRS 2019 Street Team: Peter K. Kaiser, MD
Author(s):
Dr. Kaiser discusses how risuteganib fared in a phase II trial in patients with intermediate nonexudative AMD.
Peter K. Kaiser, MD, shares the take-home message of his presentation, "Safety and Efficacy of Risuteganib in Intermediate Nonexudative Age-Related Macular Degeneration: First Time Results From a Phase 2 Study." Dr. Kaiser presented at the 2019 annual meeting of the American Society of Retina Specialists.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
